Dr Ariani presents a case series on the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs).
The series is based on cases where patient treatment included Aggrastat (tirofiban hydrochloride) injection and is intended to be an educational resource for fellows and those who may not be familiar with the use of GPIs.
These cases and testimonials are based on the experiences of a few people. Not all cases are identical. You are not likely to have similar results.
Important Safety Information about the use of Aggrastat is provided below.
Clinical studies performance with Aggrastat are provided in the full Prescribing Information.
Dr. Ariani is an interventional cardiologist working out of Dignity Northridge Hospital and Providence Cedars-Sinai Tarzana in San Fernando Valley, CA. Dr. Ariani is the Cardiovascular Service Line Director there. Here he presents three cases where he used Aggrastat in his practice:
A 66 year-old female with a history of coronary artery disease presented with chest pains. An initial coronary angiogram reveals a severely calcified lesion in the proximal to mid left anterior descending artery (LAD). Rotational atherectomy and angioplasty were performed, however, the patient developed slow flow. Intravascular ultrasound imaging revealed a significant amount of intra-arterial thrombus. See how Dr. Ariani handled this case.
53 year-old male presents to the emergency room with acute anterior wall myocardial infarction. The patient was hemodynamical unstable and was having crushing chest pain and blood pressure was quite labile. He was rushed for an urgent cardiac catheterization. Initial imaging revealed 100% occlusion of the proximal LAD. See what happened next.
69-year old female with extensive history of coronary artery disease was brought to the cardiac catheterization laboratory electively. A coronary angiography revealed a significant lesion of the LAD. An iFR measurement of the LAD was performed which equated to 0.84. A decision was made to proceed with rotational atherectomy. Watch the full video to see how Dr. Ariani approached this case.
Aggrastat (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding.
Check out the experience of other healthcare providers in the US that use Aggrastat to reduce the rate of thrombotic complications for their patients during PCI.
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).